Dynavax Technologies Corporation has released promising topline results from the first part of a Phase 1/2 clinical trial evaluating their investigational shingles vaccine candidate, Z-1018, against GSK’s Shingrix in individuals aged 50 to 69 years. The study showed that Z-1018 elicited antibody and CD4⁺ T cell responses comparable to those seen with Shingrix, with a favorable tolerability profile. Notably, Z-1018 demonstrated a 100.0% humoral vaccine response rate and an 89.7% cellular immune vaccine response rate, slightly outperforming Shingrix in these aspects.
The safety profile of Z-1018 was favorable, with low rates of moderate to severe post-injection reactions compared to Shingrix. Specifically, Z-1018 showed lower rates of grade 2 or 3 local and systemic post-injection reactions, indicating good tolerability in participants. No significant safety concerns have been raised during the ongoing blinded study, further supporting the vaccine’s safety profile and potential for further development.
Z-1018 utilizes Dynavax’s glycoprotein E antigen adjuvanted with CpG 1018, aiming to offer a novel approach to shingles vaccination. These positive results have positioned Z-1018 as a potential competitor in the shingles vaccine market, currently dominated by Shingrix. With the intention to progress to the next phase of the trial in adults aged 70 and older, Dynavax aims to establish Z-1018’s efficacy in a broader age group, setting the stage for future pivotal studies and regulatory submissions.
Dynavax’s decision to advance Z-1018 using a specific dose formulation and dosing regimen into the next phase of the trial underscores the strategic approach taken to maximize the vaccine’s potential efficacy and safety. By selecting the optimal parameters based on the early-stage study results, the company aims to build a robust clinical development plan that aligns with regulatory expectations and industry standards, ensuring a strong foundation for future success in the competitive vaccine landscape.
The positive data reported by Dynavax mark a significant milestone in the development of their shingles vaccine program, reflecting the company’s commitment to delivering a product with a best-in-class profile. As the Phase 1/2 program progresses into older adults and towards pivotal studies, the strategic decisions made based on early-stage data will be crucial in shaping the overall success of Z-1018 in challenging the existing market leader and meeting the needs of a broader population.
Takeaways:
– Dynavax’s investigational shingles vaccine, Z-1018, has shown promising results in early-stage clinical trials, demonstrating comparable immunogenicity and favorable tolerability compared to GSK’s Shingrix.
– The strategic dose formulation and dosing regimen selected for advancement into the next phase of the trial reflect Dynavax’s commitment to optimizing the vaccine’s efficacy and safety profile.
– These positive early-stage data support Dynavax’s aim to disrupt the shingles vaccine market and position Z-1018 as a potential competitor to the current market leader.
– As Dynavax progresses into older adult populations and pivotal studies, the strategic decisions based on early-stage results will be crucial in shaping the vaccine’s regulatory path and overall success.
Tags: formulation
Read more on benzinga.com